Yes, ivermectin kills hookworms in humans, but moderately rather than reliably, and it is not a first-line hookworm drug in most public-health programs. Single-dose ivermectin clears a substantial share of light infections, yet it leaves a sizable minority of worms alive, and it is less effective against hookworms than against the roundworm Ascaris. The drug paralyzes the parasite by opening glutamate-gated chloride channels, but human hookworms lack the high-affinity channel subtype that makes ivermectin so potent in some other nematodes.
Mechanism: why the drug works, and why it works imperfectly
Ivermectin binds glutamate-gated chloride channels on nematode nerve and muscle cells. Glutamate is the worm's inhibitory neurotransmitter, so opening these channels floods the cell with chloride and hyperpolarizes it. The worm's pharyngeal muscle and body-wall muscle lose the ability to contract, feeding stops, and the parasite is expelled or dies. In mammals these channels are absent or structurally different, which is the basis of the drug's safety margin.
The catch is receptor composition. Hookworms, including Necator americanus and Ancylostoma duodenale, express glutamate-gated chloride channels that ivermectin binds with lower affinity than the channels in some other nematodes. This pharmacologic detail explains the clinical pattern: excellent activity against Ascaris, weaker and more variable activity against hookworm. The drug also has a short effective window at the intestinal lumen, where adult hookworms attach and feed on blood.
Plain language: ivermectin stuns the worm rather than reliably killing it, and hookworms are harder to stun than roundworms.
Quantified context: how much killing are we talking about
The best-known comparative data come from large deworming trials. In a 2021 randomized trial in Ethiopia published in JAMA, single-dose ivermectin produced lower hookworm cure rates than albendazole, and the combination of ivermectin plus albendazole performed best (Krolewiecki et al., JAMA 2021). Across trials, single-dose ivermectin cure rates for hookworm typically fall in the range of roughly 20 to 60 percent, compared with albendazole's roughly 60 to 90 percent, though exact figures vary by species, infection intensity, and diagnostic method.
Infection intensity matters enormously. Light infections (low eggs per gram of stool) clear more often than heavy infections. A drug that removes 70 percent of worms can look effective in a light-infection population and inadequate in a heavy-infection one. This is why cure rate and egg-reduction rate are reported separately; a drug can reduce egg output substantially without curing the person.
Concrete anchors: WHO-recommended preventive chemotherapy uses albendazole or mebendazole, not ivermectin, for soil-transmitted helminths (WHO, 2017 guideline). Ivermectin's established mass-drug role is against onchocerciasis and lymphatic filariasis, where it is highly effective. Its hookworm activity is real but secondary.
Edge cases: species, coinfection, and drug interactions
Species differences are underappreciated. Ancylostoma duodenale and Necator americanus respond somewhat differently, and Ancylostoma ceylanicum, a zoonotic hookworm increasingly recognized in Southeast Asia, adds another variable. Most trials do not speciate by PCR, so reported cure rates blend species.
Coinfection with Strongyloides stercoralis is a critical edge case. Ivermectin is the preferred treatment for strongyloidiasis, and it also has activity against hookworm. In a patient with both, ivermectin treats the more dangerous infection while partly treating the hookworm, but it may not clear the hookworm. Conversely, albendazole treats hookworm well but is less reliable for Strongyloides. This trade-off shapes clinical choice in endemic regions.
Pregnancy and lactation, low body weight, and hepatic impairment change risk-benefit calculations. Ivermectin is generally avoided in pregnancy except when the benefit clearly outweighs risk, and safety data in young children are limited. These are population-level considerations, not individual prescribing advice.
Misconceptions: what ivermectin is not
Misconception one: ivermectin is a broad-spectrum dewormer that clears everything. It is broad but uneven; potency varies by species and by infection intensity.
Misconception two: a negative stool test after treatment means cure. Stool microscopy has limited sensitivity, especially at low egg counts, and a single post-treatment sample can miss residual infection.
Misconception three: mass ivermectin distribution will control hookworm. Programs that distribute ivermectin for onchocerciasis do reduce hookworm prevalence as a side effect, but albendazole-based programs remain the standard for soil-transmitted helminths because of higher and more consistent efficacy.
Misconception four: resistance is not a concern. Benzimidazole resistance in hookworms is documented in livestock and emerging in human settings; ivermectin resistance is well described in veterinary nematodes. Using the most effective drug first slows resistance.
Counterintuitive caveat: a drug can reduce community worm burden while failing to cure individuals, because egg output falls even when worms persist. Egg-reduction and cure are different endpoints, and conflating them overstates efficacy.
Practical actions: what to do with this information
Confirm the diagnosis before treating: stool microscopy or a quantitative egg count, not symptoms alone. Recognize that albendazole or mebendazole are the standard first-line agents for hookworm per WHO guidance. If ivermectin is being used for another indication (onchocerciasis, strongyloidiasis), do not assume hookworm is cleared; recheck stool if symptoms persist. Understand that combination therapy (ivermectin plus albendazole) has shown higher cure rates than either alone in trial settings (Krolewiecki et al., JAMA 2021). Red flag: heavy infection with anemia, pallor, or fatigue warrants prompt medical evaluation, not self-treatment. Red flag: ivermectin should not be self-dosed from veterinary products; human formulations differ and dosing errors are dangerous. Red flag: pregnancy, breastfeeding, or treatment of young children requires clinician guidance.
Cost and access vary by country; where albendazole is distributed free through school deworming programs, it is both cheaper and more effective for hookworm than ivermectin.
Limitations: what the evidence cannot tell you
Most efficacy trials use microscopy, which underdetects light infections, and few speciate hookworms by molecular methods. Cure rates therefore carry uncertainty that is rarely reported in headlines. Trial populations differ in baseline intensity, prior treatment history, and coinfection, so a cure rate from one setting does not transfer cleanly to another.
Ivermectin's mechanism is well established, but the precise receptor-affinity explanation for its weaker hookworm activity is inferred from veterinary and molecular studies rather than directly measured in human hookworm infections. The honest position: ivermectin kills hookworms, but incompletely and inconsistently, and the evidence supports albendazole-based regimens as the standard. Anyone weighing ivermectin for hookworm should treat it as a partial tool, not a cure, and should confirm clearance with follow-up testing rather than assuming success.
The practical bottom line for a reader searching this question: yes, it kills hookworms, but it is not the best drug for the job, and single-dose treatment often leaves worms behind.